Literature DB >> 3115161

Diabetic peripheral neuropathies.

Y Harati.   

Abstract

Diabetic peripheral neuropathies are a group of heterogeneous syndromes with considerable morbidity. At least 50% of diabetic patients develop one or several of these neuropathies within 25 years after the diagnosis. In recent years several pathogenetic mechanisms have been proposed, with the newest findings suggesting a link between several of these hypotheses. The hypoxic hypothesis has revived the role of vascular factors in the pathogenesis of diabetic peripheral neuropathies. Although the exact role of hyperglycemia in the development of peripheral neuropathy is not known, the balance of evidence indicates that attainment and maintenance of normal blood glucose remains the cornerstone of treatment of diabetes and diabetic neuropathies. There is no convincing evidence that any of the treatments devised to correct the metabolic derangements in nerve are of sufficient value or safety to be recommended for routine use.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3115161     DOI: 10.7326/0003-4819-107-4-546

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  12 in total

1.  Burning leg pain during spinal anesthesia in a diabetic patient.

Authors:  T Harioka; K Nomura; T Ito; M Kakuyama
Journal:  J Anesth       Date:  1993-07       Impact factor: 2.078

2.  The medial plantar and medial peroneal cutaneous nerve conduction studies for diabetic polyneuropathy.

Authors:  Yasar Altun; Ahmet Demirkol; Yener Tumay; Kazım Ekmekci; Ibrahim Unsal; Ahmet Candan Koyluoglu; Yasar Ozkul
Journal:  Neurol Sci       Date:  2011-07-01       Impact factor: 3.307

3.  Randomized double-blind placebo-controlled trial to evaluate the effect of the ACTH4-9 analogue ORG 2766 in IDDM patients with neuropathy.

Authors:  B Bravenboer; P H Hendrikse; P L Oey; A C van Huffelen; C Groenhout; W H Gispen; D W Erkelens
Journal:  Diabetologia       Date:  1994-04       Impact factor: 10.122

4.  Blocking mitochondrial calcium release in Schwann cells prevents demyelinating neuropathies.

Authors:  Sergio Gonzalez; Jade Berthelot; Jennifer Jiner; Claire Perrin-Tricaud; Ruani Fernando; Roman Chrast; Guy Lenaers; Nicolas Tricaud
Journal:  J Clin Invest       Date:  2016-02-15       Impact factor: 14.808

Review 5.  Vascular factors in diabetic neuropathy.

Authors:  S Tesfaye; R Malik; J D Ward
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

6.  Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA.

Authors:  T Yamaoka; C Nishimura; K Yamashita; M Itakura; T Yamada; J Fujimoto; Y Kokai
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

7.  Diabetes-induced changes in cardiac beta-adrenoceptor responsiveness: effects of aldose reductase inhibition with ponalrestat.

Authors:  C E Austin; R Chess-Williams
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

Review 8.  The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.

Authors:  J M van Gerven; A M Tjon-A-Tsien
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

9.  Electroneurography of right median and ulnar nerves in diabetic patients with and without retinopathy.

Authors:  Emir Tupković; Suzana Pavljesević; Mediha Nisić; Samiha Salihović
Journal:  Bosn J Basic Med Sci       Date:  2007-08       Impact factor: 3.363

Review 10.  Management of painful diabetic neuropathy.

Authors:  P G Jensen; J R Larson
Journal:  Drugs Aging       Date:  2001       Impact factor: 4.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.